Lantern Historical Balance Sheet

LTRN Stock

USD 3.21 0.10 3.22%

Trend analysis of Lantern Pharma balance sheet accounts such as Total Stockholder Equity of 34.6 M provides information on Lantern Pharma's total assets, liabilities, and equity, which is the actual value of Lantern Pharma to its prevalent stockholders. By breaking down trends over time using Lantern Pharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Lantern Pharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Lantern Pharma is a good buy for the upcoming year.

Lantern Pharma Inventory

(559,440)

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lantern Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.

About Lantern Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Lantern Pharma at a specified time, usually calculated after every quarter, six months, or one year. Lantern Pharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Lantern Pharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Lantern currently owns. An asset can also be divided into two categories, current and non-current.

Lantern Pharma Balance Sheet Chart

At this time, Lantern Pharma's Property Plant Equipment is very stable compared to the past year. As of the 30th of November 2024, Property Plant And Equipment Gross is likely to grow to about 294.4 K, while Total Assets are likely to drop about 36.4 M.

Total Assets Total Current Liabilities Short Term Investments Capital Lease Obligations

Add Fundamental

Total Assets

Total assets refers to the total amount of Lantern Pharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Lantern Pharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Lantern Pharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Lantern Pharma are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Short Term Investments

Short Term Investments is an item under the current assets section of Lantern Pharma balance sheet. It contains any investments Lantern Pharma undertook that will expire in less than one year. These accounts contain financial instruments such as stocks or bonds that Lantern Pharma can easily liquidate in the marketplace.

Capital Lease Obligations

Lantern Pharma capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Lantern Pharma asset purchases. For example, Lantern Pharma can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Lantern Pharma control over an asset for a big portion of its life. The total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee.

Most accounts from Lantern Pharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Lantern Pharma current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lantern Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.At this time, Lantern Pharma's Property Plant Equipment is very stable compared to the past year. As of the 30th of November 2024, Property Plant And Equipment Gross is likely to grow to about 294.4 K, while Total Assets are likely to drop about 36.4 M.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	1.5M	1.8M	2.5M	1.3M
Total Assets	74.0M	58.8M	43.6M	36.4M

Other Current Liab Total Assets

Lantern Pharma balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Capital Surpluse	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Common Stock	Property Plant Equipment	Other Assets	Other Current Assets
Total Assets		0.76	0.92	1.0	0.98	0.79	-0.99	-0.79	0.62	0.99	0.8	0.03	1.0	-0.89	0.95	0.92	0.97	0.93	1.0	1.0	-0.88	1.0	-0.89	0.86	0.39	0.82
Other Current Liab	0.76		0.94	0.75	0.85	0.81	-0.65	-0.86	0.75	0.65	0.46	-0.19	0.76	-0.63	0.91	0.84	0.86	0.94	0.75	0.76	-0.64	0.75	-0.63	0.53	0.03	0.73
Total Current Liabilities	0.92	0.94		0.92	0.95	0.82	-0.85	-0.88	0.72	0.85	0.59	-0.11	0.92	-0.8	0.99	0.92	0.97	1.0	0.92	0.92	-0.8	0.92	-0.8	0.68	0.14	0.88
Total Stockholder Equity	1.0	0.75	0.92		0.98	0.79	-0.99	-0.78	0.61	0.99	0.8	0.03	1.0	-0.89	0.95	0.91	0.97	0.92	1.0	1.0	-0.88	1.0	-0.89	0.87	0.39	0.82
Net Tangible Assets	0.98	0.85	0.95	0.98		0.84	-0.94	-0.84	0.69	0.94	0.76	0.02	0.98	-0.89	0.97	0.93	0.99	0.96	0.98	0.98	-0.88	0.98	-0.89	0.81	0.31	0.81
Property Plant And Equipment Net	0.79	0.81	0.82	0.79	0.84		-0.73	-0.93	0.93	0.74	0.67	0.03	0.79	-0.8	0.87	0.94	0.85	0.83	0.79	0.79	-0.78	0.79	-0.8	0.69	0.14	0.62
Net Debt	-0.99	-0.65	-0.85	-0.99	-0.94	-0.73		0.71	-0.53	-1.0	-0.82	-0.07	-0.99	0.89	-0.89	-0.86	-0.93	-0.86	-0.99	-0.99	0.87	-0.99	0.89	-0.88	-0.45	-0.78
Retained Earnings	-0.79	-0.86	-0.88	-0.78	-0.84	-0.93	0.71		-0.96	-0.72	-0.45	-0.08	-0.78	0.85	-0.89	-0.96	-0.88	-0.89	-0.78	-0.79	0.83	-0.78	0.84	-0.51	0.15	-0.81
Accounts Payable	0.62	0.75	0.72	0.61	0.69	0.93	-0.53	-0.96		0.54	0.38	0.17	0.61	-0.74	0.75	0.88	0.73	0.73	0.61	0.62	-0.71	0.61	-0.74	0.39	-0.23	0.63
Cash	0.99	0.65	0.85	0.99	0.94	0.74	-1.0	-0.72	0.54		0.82	0.07	0.99	-0.89	0.9	0.87	0.93	0.86	0.99	0.99	-0.88	0.99	-0.89	0.88	0.45	0.78
Non Current Assets Total	0.8	0.46	0.59	0.8	0.76	0.67	-0.82	-0.45	0.38	0.82		0.13	0.8	-0.61	0.69	0.65	0.7	0.6	0.8	0.79	-0.57	0.8	-0.61	0.98	0.79	0.32
Non Currrent Assets Other	0.03	-0.19	-0.11	0.03	0.02	0.03	-0.07	-0.08	0.17	0.07	0.13		0.03	-0.18	-0.04	0.06	0.04	-0.09	0.03	0.03	-0.01	0.03	-0.19	0.0	-0.1	0.04
Cash And Short Term Investments	1.0	0.76	0.92	1.0	0.98	0.79	-0.99	-0.78	0.61	0.99	0.8	0.03		-0.89	0.95	0.91	0.97	0.93	1.0	1.0	-0.88	1.0	-0.89	0.87	0.39	0.82
Common Stock Total Equity	-0.89	-0.63	-0.8	-0.89	-0.89	-0.8	0.89	0.85	-0.74	-0.89	-0.61	-0.18	-0.89		-0.83	-0.91	-0.91	-0.82	-0.89	-0.89	0.98	-0.89	1.0	-0.66	-0.08	-0.82
Common Stock Shares Outstanding	0.95	0.91	0.99	0.95	0.97	0.87	-0.89	-0.89	0.75	0.9	0.69	-0.04	0.95	-0.83		0.95	0.98	0.99	0.95	0.95	-0.82	0.95	-0.83	0.76	0.23	0.85
Capital Surpluse	0.92	0.84	0.92	0.91	0.93	0.94	-0.86	-0.96	0.88	0.87	0.65	0.06	0.91	-0.91	0.95		0.96	0.93	0.91	0.92	-0.9	0.91	-0.91	0.7	0.09	0.84
Other Stockholder Equity	0.97	0.86	0.97	0.97	0.99	0.85	-0.93	-0.88	0.73	0.93	0.7	0.04	0.97	-0.91	0.98	0.96		0.98	0.97	0.97	-0.89	0.97	-0.91	0.76	0.22	0.87
Total Liab	0.93	0.94	1.0	0.92	0.96	0.83	-0.86	-0.89	0.73	0.86	0.6	-0.09	0.93	-0.82	0.99	0.93	0.98		0.92	0.93	-0.82	0.93	-0.82	0.69	0.14	0.88
Net Invested Capital	1.0	0.75	0.92	1.0	0.98	0.79	-0.99	-0.78	0.61	0.99	0.8	0.03	1.0	-0.89	0.95	0.91	0.97	0.92		1.0	-0.88	1.0	-0.89	0.87	0.39	0.82
Total Current Assets	1.0	0.76	0.92	1.0	0.98	0.79	-0.99	-0.79	0.62	0.99	0.79	0.03	1.0	-0.89	0.95	0.92	0.97	0.93	1.0		-0.88	1.0	-0.89	0.86	0.38	0.83
Capital Stock	-0.88	-0.64	-0.8	-0.88	-0.88	-0.78	0.87	0.83	-0.71	-0.88	-0.57	-0.01	-0.88	0.98	-0.82	-0.9	-0.89	-0.82	-0.88	-0.88		-0.88	0.98	-0.65	-0.09	-0.81
Net Working Capital	1.0	0.75	0.92	1.0	0.98	0.79	-0.99	-0.78	0.61	0.99	0.8	0.03	1.0	-0.89	0.95	0.91	0.97	0.93	1.0	1.0	-0.88		-0.89	0.86	0.39	0.82
Common Stock	-0.89	-0.63	-0.8	-0.89	-0.89	-0.8	0.89	0.84	-0.74	-0.89	-0.61	-0.19	-0.89	1.0	-0.83	-0.91	-0.91	-0.82	-0.89	-0.89	0.98	-0.89		-0.66	-0.09	-0.82
Property Plant Equipment	0.86	0.53	0.68	0.87	0.81	0.69	-0.88	-0.51	0.39	0.88	0.98	0.0	0.87	-0.66	0.76	0.7	0.76	0.69	0.87	0.86	-0.65	0.86	-0.66		0.77	0.43
Other Assets	0.39	0.03	0.14	0.39	0.31	0.14	-0.45	0.15	-0.23	0.45	0.79	-0.1	0.39	-0.08	0.23	0.09	0.22	0.14	0.39	0.38	-0.09	0.39	-0.09	0.77		-0.15
Other Current Assets	0.82	0.73	0.88	0.82	0.81	0.62	-0.78	-0.81	0.63	0.78	0.32	0.04	0.82	-0.82	0.85	0.84	0.87	0.88	0.82	0.83	-0.81	0.82	-0.82	0.43	-0.15

Click cells to compare fundamentals

Lantern Pharma Account Relationship Matchups

Lantern Pharma balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.4M	20.4M	74.0M	58.8M	43.6M	36.4M
Other Current Liab	489.3K	120K	1.5M	1.8M	2.5M	1.3M
Total Current Liabilities	489.3K	552.3K	2.3M	2.8M	2.7M	1.7M
Total Stockholder Equity	943.3K	19.7M	71.6M	56.0M	40.9M	34.6M
Net Tangible Assets	943.0K	19.7M	71.6M	56.0M	64.4M	32.6M
Property Plant And Equipment Net	8.8K	21.5K	216.2K	95.7K	280.4K	294.4K
Net Debt	(1.2M)	(19.1M)	(51.3M)	(37.1M)	(21.7M)	(22.8M)
Retained Earnings	(6.8M)	(12.7M)	(25.0M)	(39.3M)	(55.2M)	(52.5M)
Accounts Payable	489.3K	432.3K	681.1K	932.4K	2.5M	2.6M
Cash	1.2M	19.2M	51.5M	37.2M	21.9M	24.1M
Non Current Assets Total	199.8K	122.7K	1.2M	113.6K	306.3K	363.2K
Cash And Short Term Investments	1.2M	19.2M	70.7M	55.2M	41.3M	34.5M
Common Stock Shares Outstanding	6.3M	6.2M	10.9M	10.9M	10.8M	9.4M
Liabilities And Stockholders Equity	1.4M	20.4M	74.0M	58.8M	43.6M	36.4M
Other Stockholder Equity	7.7M	32.4M	96.7M	95.7M	96.3M	61.0M
Total Liab	489.3K	660.8K	2.4M	2.8M	2.7M	1.8M
Net Invested Capital	929.3K	19.8M	71.6M	56.0M	40.9M	34.7M
Total Current Assets	1.2M	20.2M	72.7M	58.7M	43.3M	36.1M
Capital Stock	25.4K	622.0	1.1K	1.1K	1.1K	1.0K
Net Working Capital	743.5K	19.7M	70.4M	55.9M	40.7M	34.3M
Property Plant Equipment	8.8K	21.5K	216.2K	48.0K	55.2K	65.8K

Pair Trading with Lantern Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lantern Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lantern Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with Lantern Stock

0.61

ELAN

Elanco Animal Health

Pair Corr

Moving against Lantern Stock

0.71	BMY	Bristol Myers Squibb Sell-off Trend	Pair Corr
0.7	ESPR	Esperion Therapeutics Buyout Trend	Pair Corr
0.53	EWTX	Edgewise Therapeutics	Pair Corr
0.53	GILD	Gilead Sciences	Pair Corr
0.46	EBS	Emergent Biosolutions	Pair Corr

The ability to find closely correlated positions to Lantern Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lantern Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lantern Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lantern Pharma to buy it.

The correlation of Lantern Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lantern Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lantern Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Lantern Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Lantern Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lantern Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lantern Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lantern Pharma Stock:

How To Invest In Lantern

Details

Is Lantern Stock a good investment?

Details

What is Lantern Pharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.

You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.78)

Return On Assets

(0.28)

Return On Equity

(0.45)

The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lantern Historical Balance Sheet

Lantern Pharma Inventory

(559,440)

About Lantern Balance Sheet Analysis

Lantern Pharma Balance Sheet Chart

Total Assets

Total Current Liabilities

Short Term Investments

Capital Lease Obligations

Lantern Pharma balance sheet Correlations

Lantern Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Lantern Pharma balance sheet Accounts

Pair Trading with Lantern Pharma

Moving together with Lantern Stock

Moving against Lantern Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities

Cash	- 1.0	Net Debt
Net Working Capital	- 0.99	Net Debt
Total Current Assets	- 0.99	Net Debt
Net Invested Capital	- 0.99	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Net Debt	- 0.99	Total Stockholder Equity